David R. Epstein
CIK: 0001445826
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (22 total)
- Oct 21, 2026AGMB
AgomAb Therapeutics NV
Purchase(P)Direct5K shares at avg. $8.90$45K - Oct 21, 2026AGMB
AgomAb Therapeutics NV
Purchase(P)Direct5K shares at avg. $8.86$44K - Oct 8, 2026AGMB
AgomAb Therapeutics NV
Purchase(P)Direct5K shares at avg. $8.90$45K - Oct 6, 2026AGMB
AgomAb Therapeutics NV
Purchase(P)Direct5K shares at avg. $8.70$44K - Oct 5, 2026AGMB
AgomAb Therapeutics NV
Purchase(P)Direct5K shares at avg. $8.57$43K - Sep 1, 2026TEM
Tempus AI, Inc.
Sale(S)Direct250 shares at avg. $65.55$16K - Aug 3, 2026TEM
Tempus AI, Inc.
Sale(S)Direct370 shares at avg. $43.40$16K - Jun 1, 2026TEM
Tempus AI, Inc.
Sale(S)Direct250 shares at avg. $49.40$12K - May 21, 2026TEM
Tempus AI, Inc.
Award(A)Direct5.9K shares- - Mar 2, 2026TEM
Tempus AI, Inc.
Sale(S)Direct250 shares at avg. $50.69$13K - Feb 2, 2026TEM
Tempus AI, Inc.
Sale(S)Direct370 shares at avg. $59.41$22K - Dec 1, 2025TEM
Tempus AI, Inc.
Sale(S)Direct250 shares at avg. $75.55$19K - Nov 3, 2025TEM
Tempus AI, Inc.
Sale(S)Direct370 shares at avg. $90.00$33K - Sep 2, 2025TEM
Tempus AI, Inc.
Sale(S)Direct250 shares at avg. $73.64$18K - Aug 1, 2025TEM
Tempus AI, Inc.
Sale(S)Direct370 shares at avg. $55.16$20K - Jun 2, 2025TEM
Tempus AI, Inc.
Sale(S)Direct250 shares at avg. $55.20$14K - May 20, 2025TEM
Tempus AI, Inc.
Award(A)Direct2K shares- - May 1, 2025TEM
Tempus AI, Inc.
Sale(S)Direct370 shares at avg. $53.50$20K - Mar 17, 2025TEM
Tempus AI, Inc.
Sale(S)Direct990 shares at avg. $46.83$46K - Mar 3, 2025TEM
Tempus AI, Inc.
Sale(S)Direct250 shares at avg. $57.52$14K - Feb 3, 2025TEM
Tempus AI, Inc.
Sale(S)Direct370 shares at avg. $53.31$20K - Dec 11, 2024TEM
Tempus AI, Inc.
Sale(S)Direct620 shares at avg. $41.81$26K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Oct 21, 2026 |  AGMB AgomAb Therapeutics NV | Purchase(P) | 5,000 | $8.90 | $44,500 | Direct |
| Oct 21, 2026 | AGMB AgomAb Therapeutics NV | Purchase(P) | 5,000 | $8.86 | $44,300 | Direct |
| Oct 8, 2026 | AGMB AgomAb Therapeutics NV | Purchase(P) | 5,000 | $8.90 | $44,500 | Direct |
| Oct 6, 2026 | AGMB AgomAb Therapeutics NV | Purchase(P) | 5,000 | $8.70 | $43,500 | Direct |
| Oct 5, 2026 | AGMB AgomAb Therapeutics NV | Purchase(P) | 5,000 | $8.57 | $42,850 | Direct |
| Sep 1, 2026 |  TEM Tempus AI, Inc. | Sale(S) | 250 | $65.55 | $16,388 | Direct |
| Aug 3, 2026 | TEM Tempus AI, Inc. | Sale(S) | 370 | $43.40 | $16,058 | Direct |
| Jun 1, 2026 | TEM Tempus AI, Inc. | Sale(S) | 250 | $49.40 | $12,350 | Direct |
| May 21, 2026 | TEM Tempus AI, Inc. | Award(A) | 5,913 | - | $0 | Direct |
| Mar 2, 2026 | TEM Tempus AI, Inc. | Sale(S) | 250 | $50.69 | $12,673 | Direct |
| Feb 2, 2026 | TEM Tempus AI, Inc. | Sale(S) | 370 | $59.41 | $21,982 | Direct |
| Dec 1, 2025 | TEM Tempus AI, Inc. | Sale(S) | 250 | $75.55 | $18,888 | Direct |
| Nov 3, 2025 | TEM Tempus AI, Inc. | Sale(S) | 370 | $90.00 | $33,300 | Direct |
| Sep 2, 2025 | TEM Tempus AI, Inc. | Sale(S) | 250 | $73.64 | $18,410 | Direct |
| Aug 1, 2025 | TEM Tempus AI, Inc. | Sale(S) | 370 | $55.16 | $20,409 | Direct |
| Jun 2, 2025 | TEM Tempus AI, Inc. | Sale(S) | 250 | $55.20 | $13,800 | Direct |
| May 20, 2025 | TEM Tempus AI, Inc. | Award(A) | 1,997 | - | - | Direct |
| May 1, 2025 | TEM Tempus AI, Inc. | Sale(S) | 370 | $53.50 | $19,795 | Direct |
| Mar 17, 2025 | TEM Tempus AI, Inc. | Sale(S) | 990 | $46.83 | $46,362 | Direct |
| Mar 3, 2025 | TEM Tempus AI, Inc. | Sale(S) | 250 | $57.52 | $14,380 | Direct |
| Feb 3, 2025 | TEM Tempus AI, Inc. | Sale(S) | 370 | $53.31 | $19,725 | Direct |
| Dec 11, 2024 | TEM Tempus AI, Inc. | Sale(S) | 620 | $41.81 | $25,922 | Direct |
1-22 of 22 transactions
About Epstein David R
Epstein David R (SEC CIK 0001445826) files insider reports with the SEC as Director of AgomAb Therapeutics NV (AGMB) and Director of Tempus AI, Inc. (TEM).
Signal8 holds 21 ownership filings by Epstein David R (1 Form 3, 20 Form 4), filed between Dec 13, 2024 and Oct 22, 2026. Those filings report 22 transactions, from Dec 11, 2024 to Oct 21, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Epstein David R's filings is in DELRAY BEACH, FL.
Recent filings by Epstein David R
- Oct 21, 2026: Open-market purchases of AGMB shares (2 lines, Form 4, code P).
- Oct 8, 2026: Open-market purchase of AGMB shares (Form 4, code P).
- Oct 6, 2026: Open-market purchase of AGMB shares (Form 4, code P).
- Oct 5, 2026: Open-market purchase of AGMB shares (Form 4, code P).
- Sep 1, 2026: Open-market sale of TEM shares (Form 4, code S).
Other insiders filing for AgomAb Therapeutics NV (AGMB)
- Kemula Pierre Thadee Victor, Chief Financial Officer
- Knotnerus Tim Jasper, Chief Executive Officer
- Garcia Marino, Director
- Patel Naimish, Director
- Bond Colin Michael, Director
- Hammer Ohad, Director